Cargando…

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate

The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized X...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uraki, Ryuta, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Sakai-Tagawa, Yuko, Imai, Masaki, Koga, Michiko, Yamamoto, Shinya, Adachi, Eisuke, Saito, Makoto, Tsutsumi, Takeya, Otani, Amato, Fukushi, Shuetsu, Watanabe, Shinji, Suzuki, Tadaki, Kikuchi, Tetsuhiro, Yotsuyanagi, Hiroshi, Maeda, Ken, Kawaoka, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590837/ https://www.ncbi.nlm.nih.gov/pubmed/37876803 http://dx.doi.org/10.1016/j.isci.2023.108147

Ejemplares similares

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

Previous omicron infection may be protective against reinfection with omicron variant BA.5 for at least 5 months
por: Koga, Michiko, et al.
Publicado: (2023)

Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose COVID-19: A Case Report in Japan
por: Saito, Makoto, et al.
Publicado: (2020)

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus
por: SONI, Priyanka, et al.
Publicado: (2018)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization
por: Mizutani, Taketoshi, et al.
Publicado: (2022)

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies
por: Yasuhara, Atsuhiro, et al.
Publicado: (2017)

In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
por: Furusawa, Yuri, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
por: Uraki, Ryuta, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018
por: Okuda, Moe, et al.
Publicado: (2019)

Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
por: Ravichandran, Supriya, et al.
Publicado: (2021)

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
por: Yamayoshi, Seiya, et al.
Publicado: (2017)

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene
por: Wu, Nicholas C., et al.
Publicado: (2018)

Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan
por: Soga, Takuma, et al.
Publicado: (2023)

Antigenic variants of influenza B viruses isolated in Japan during the 2017‐2018 and 2018‐2019 influenza seasons
por: Kato‐Miyashita, Sari, et al.
Publicado: (2020)

Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan
por: Yamayoshi, Seiya, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
por: Takashita, Emi, et al.
Publicado: (2022)

Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans
por: Yamayoshi, Seiya, et al.
Publicado: (2018)

Isolation and Characterization of Human Monoclonal Antibodies That Recognize the Influenza A(H1N1)pdm09 Virus Hemagglutinin Receptor-Binding Site and Rarely Yield Escape Mutant Viruses
por: Yasuhara, Atsuhiro, et al.
Publicado: (2018)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
por: Kawaoka, Yoshihiro, et al.
Publicado: (2022)

Triple combination therapy of favipiravir plus two monoclonal antibodies eradicates influenza virus from nude mice
por: Kiso, Maki, et al.
Publicado: (2020)

A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases
por: Yasuhara, Atsuhiro, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

Favorable Outcome Following Sotrovimab Monoclonal Antibody in a Patient with Prolonged SARS-CoV-2 Omicron Infection with HIV/AIDS
por: Adachi, Eisuke, et al.
Publicado: (2022)

Comparison of Rapid Antigen Tests for COVID-19
por: Yamayoshi, Seiya, et al.
Publicado: (2020)

The Marmoset as an Animal Model of Influenza: Infection With A(H1N1)pdm09 and Highly Pathogenic A(H5N1) Viruses via the Conventional or Tracheal Spray Route
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Sensitivity of Commercially Available Influenza Rapid Diagnostic Tests in the 2018–2019 Influenza Season
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7i60hlj73i0agkg82b9j5hacb9